Teva Reports 3-Year (ARC-HD) Study Results of Austedo (deutetrabenazine) for the Treatment of Chorea Associated with Huntington’s Disease
Shots:
- The 3yr. (ARC-HD) extension study evaluating Austedo in 119 patients (82 completed First-HD trial in Rollover cohort & 37 converted overnight from a stable tetrabenazine dose to Austedo in Switch cohort) with chorea associated with HD. The study was conducted by Teva in collaboration with the Huntington Study Group
- The results showed a safety & tolerability profile over (First-HD) 12wk. study, improved & maintained chorea control in rollover & switch cohorts
- Patients rolled over from the pivotal study & switched overnight from tetrabenazine from baseline to 8wk. showed a 4.5 & 2.1-point reduction in mean chorea scores; 7.1 & 2.4-point in mean TMS, reductions in TMC were maintained for all patients in both cohorts from 8 to 145wk.
Ref: Buisnesswire | Image: Teva
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
